Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory That Expresses E-selectin Ligand on the Cell Membrane

Clinical trial NCT05146739 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT05146739
Sponsor: National Cancer Institute (NCI)
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Acute Myeloid Leukemia Post Cytotoxic Therapy Myelodysplastic Syndrome Post Cytotoxic Therapy Myeloid Leukemia Associated With Down Syndrome Recurrent Acute Myeloid Leukemia Recurrent Mixed Phenotype Acute Leukemia Recurrent Myelodysplastic Syndrome Refractory Acute Myeloid Leukemia Refractory Mixed Phenotype Acute Leukemia Refractory Myelodysplastic Syndrome

Start date: 2023-10-10
Primary completion: 2025-03-31
Enrollment: 8

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.